On January 18, 2025, President Trump signed an executive order directing the Food and Drug Administration to expedite its review process for psychedelic drug treatments, specifically naming ibogaine as a priority substance for accelerated approval pathways. The directive targets the FDA's standard review timeline, compelling the agency to compress evaluation periods for psychedelic-based therapies without specifying which statutory authorities or procedural modifications would govern the acceleration. The order frames the initiative primarily around treating post-traumatic stress disorder in military veterans, positioning the reform as both a healthcare and veterans' benefits measure.

The direct beneficiaries would include military veterans currently excluded from access to ibogaine and other psychedelic treatments, as well as civilians with PTSD and other mental health conditions who might gain earlier access to these therapies through expedited FDA pathways. However, the acceleration mechanism raises questions about the evaluation standards applied to safety and efficacy data, given that ibogaine carries documented risks including cardiac complications and potential neurotoxicity. Veterans' advocacy groups have emphasized potential therapeutic benefits for treatment-resistant PTSD, but compressed review timelines necessarily reduce the scrutiny applied to medical evidence.

This action fits a broader pattern of FDA deregulation under Trump's second administration. The authorization of fruit-flavored vapes in May 2026 similarly reflected pressure on FDA leadership to eliminate restrictions, though that case involved relaxing consumer protections rather than accelerating new drug access. The psychedelic order contrasts with simultaneous restrictions on reproductive health access, such as the mifepristone telehealth ruling and Title X reorientation away from contraception provision, suggesting selective deregulation favoring certain therapeutic categories while constraining others. The inconsistent regulatory approach complicates the administration's stated commitment to accelerated medical innovation.

As of early 2025, no court challenges to the psychedelic review acceleration have been documented, though patient advocacy groups and medical associations may contest the procedural modifications if they perceive them as inadequately protective of safety standards. Congressional oversight committees have not yet formally responded to the executive order.